by Robert Sheard (MF DowMan) LEXINGTON, Ky. (Apr. 10): Despite the swift and mighty sell-off in the DJIA, some technology stocks fared reasonably well today, with the Nasdaq Composite only dropping a few points.
One such bright spot was Tellabs, a carry-over stock from last quarter's IFG portfolio. Tellabs is now in its third quarter as an IFG stock and is just starting to show a gain for the portfolio after lagging for many months. Today's earnings release bodes well for the company's - and the stock's - future.
Analysts were expecting $0.32 per share for the quarter, but Tellabs managed to beat that by two cents. Duff & Phelps analyst James McIlree stressed that "business was strong across the board for them." And Oppenheimer analyst Steven Levy boosted his estimates for 1996 to $1.65 per share from $1.62. For 1997, he raised them from $2.06 to $2.10. Levy was particularly pleased to see Tellabs' typically weak March quarter come in above estimates.
In a bit of analyst guiding, Medtronic's chief financial officer, Robert Ryan, told analysts that he's comfortable with the $1.87 earnings estimates the Street has for FY 1996 (ending in April). "As a company, we don't forecast earnings," Ryan said. "But I will say I'm comfortable with this estimate." He went on to say that Medtronic "will achieve revenues this year of $2.2 billion."
In a coda to yesterday's stories on Oracle, SoundView analyst Jim Mendelson lowered his short-term rating on the software company's stock from Buy to Hold. Long-term, the rating remains a Buy and Mendelson left his earnings estimates at $1.53 for 1996 and $2.00 for 1997.
In the Relative Strength portfolio, Thermo Electron <% if gsSubBrand = "aolsnapshot" then Response.Write("(NYSE: TMO)") else Response.Write("(NYSE: TMO)") end if %> has signed a letter of intent to acquire SensorMedics Corporation, a privately held manufacturer of medical equipment based in Yorba Linda, California. SensorMedics specializes in systems for pulmonary function diagnosis, including high-frequency ventilation for pediatric and neonatal use. Reported sales for SensorMedics in 1995 totaled $62.8 million.
The Relative Strength models (both the monthly and quarterly versions) actually bucked the market and gained a fraction today. That's what we hope to see on down days.
Transmitted: 4/10/96 | ||||||||
INVESTING FOR GROWTH (4/10/96) | ||||||||
| ||||||||